CCL16 Inhibitors
CCL16 inhibitors are chemical compounds designed to specifically interact with and inhibit the chemokine CCL16, also known as liver-expressed chemokine (LEC). CCL16 is part of the CC chemokine family, which is involved in regulating the movement and activity of immune cells, such as monocytes and lymphocytes, through chemotactic gradients. CCL16 binds to multiple receptors, including CCR1, CCR2, CCR5, and CCR8, each of which triggers different downstream signaling pathways. The inhibition of CCL16 interferes with its ability to activate these receptors, thus preventing the chemokine from exerting its usual biological effects, such as cell recruitment, migration, and activation in response to various physiological signals. The chemokine CCL16 is expressed in specific tissues, particularly in the liver, but its expression can also be found in other contexts, especially in response to inflammatory stimuli.
The chemical structures of CCL16 inhibitors are typically optimized to ensure high specificity and affinity for the CCL16 chemokine or its interacting receptors. These inhibitors may be composed of small molecules, peptides, or larger biologic agents that bind to either CCL16 itself or its receptor-binding sites. In doing so, they disrupt the molecular interaction between CCL16 and its receptors, leading to the modulation of the downstream signaling pathways activated by this chemokine. The development of such inhibitors requires a deep understanding of the three-dimensional structure of CCL16 and its interaction surfaces with the corresponding receptors. This process also involves considerations related to the inhibitor's stability, solubility, and binding characteristics, which are crucial for effectively blocking CCL16-mediated signaling and its associated cellular functions.
SEE ALSO...
Items 1 to 10 of 12 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Dexamethasone | 50-02-2 | sc-29059 sc-29059B sc-29059A | 100 mg 1 g 5 g | $91.00 $139.00 $374.00 | 36 | |
Dexamethasone may downregulate CCL16 expression by activating glucocorticoid receptors, which can suppress pro-inflammatory cytokine production, including CCL16, through the inhibition of NF-κB and AP-1 transcription factors. | ||||||
Aspirin | 50-78-2 | sc-202471 sc-202471A | 5 g 50 g | $20.00 $42.00 | 4 | |
Aspirin could decrease CCL16 expression by blocking cyclooxygenase enzymes, leading to reduced prostaglandin synthesis, which may lower the inflammatory stimulus required for CCL16 production. | ||||||
Rolipram | 61413-54-5 | sc-3563 sc-3563A | 5 mg 50 mg | $77.00 $216.00 | 18 | |
Rolipram may lead to a reduction in CCL16 expression by elevating cAMP levels, which could inhibit NF-κB-mediated transcription of inflammatory cytokines, including CCL16, in immune cells. | ||||||
SP600125 | 129-56-6 | sc-200635 sc-200635A | 10 mg 50 mg | $40.00 $150.00 | 257 | |
SP600125 could inhibit CCL16 expression by targeting c-Jun N-terminal kinase (JNK), a kinase that, when inhibited, may prevent activation of transcription factors crucial for CCL16 gene transcription. | ||||||
PD 98059 | 167869-21-8 | sc-3532 sc-3532A | 1 mg 5 mg | $40.00 $92.00 | 212 | |
PD 98059 may directly inhibit MEK, which is upstream of ERK in the MAP kinase pathway, leading to decreased ERK activation and potentially resulting in reduced transcriptional activity of the CCL16 gene. | ||||||
BAY 11-7082 | 19542-67-7 | sc-200615B sc-200615 sc-200615A | 5 mg 10 mg 50 mg | $62.00 $85.00 $356.00 | 155 | |
Bay 11-7082 may decrease CCL16 expression by blocking the phosphorylation of IκB-α, preventing the subsequent release and nuclear translocation of NF-κB, a key regulator of CCL16 transcription. | ||||||
Curcumin | 458-37-7 | sc-200509 sc-200509A sc-200509B sc-200509C sc-200509D sc-200509F sc-200509E | 1 g 5 g 25 g 100 g 250 g 1 kg 2.5 kg | $37.00 $69.00 $109.00 $218.00 $239.00 $879.00 $1968.00 | 47 | |
Curcumin may inhibit CCL16 expression by directly inhibiting the activity of transcription factors NF-κB and STAT3, both of which are implicated in the transcriptional activation of the CCL16 gene. | ||||||
(−)-Epigallocatechin Gallate | 989-51-5 | sc-200802 sc-200802A sc-200802B sc-200802C sc-200802D sc-200802E | 10 mg 50 mg 100 mg 500 mg 1 g 10 g | $43.00 $73.00 $126.00 $243.00 $530.00 $1259.00 | 11 | |
Epigallocatechin Gallate is likely to decrease CCL16 expression by inhibiting NF-κB activity, which might otherwise bind to the CCL16 promoter region and promote its transcription in response to inflammatory stimuli. | ||||||
Wogonin, S. baicalensis | 632-85-9 | sc-203313 | 10 mg | $200.00 | 8 | |
Wogonin may suppress CCL16 expression by inhibiting the phosphorylation and activation of STAT3 and NF-κB, transcription factors that are involved in the signalling pathways leading to the production of CCL16. | ||||||
Quercetin | 117-39-5 | sc-206089 sc-206089A sc-206089E sc-206089C sc-206089D sc-206089B | 100 mg 500 mg 100 g 250 g 1 kg 25 g | $11.00 $17.00 $110.00 $250.00 $936.00 $50.00 | 33 | |
Quercetin may inhibit CCL16 expression by hindering the activation of PI3K-Akt and NF-κB pathways, which play a role in the transcriptional activation of genes involved in the inflammatory response, including CCL16. | ||||||